Yes, Zepbound (tirzepatide) can cause hives (urticaria)
Hives and other hypersensitivity reactions, including urticaria and angioedema, have been documented with tirzepatide (Zepbound), though they are uncommon. These reactions can occur at any point during treatment, including after dose escalation, and may require discontinuation of the medication.
Evidence of Urticaria with Tirzepatide
The most recent clinical evidence confirms tirzepatide-associated urticaria:
- Case reports document confirmed hypersensitivity reactions including generalized urticaria and angioedema occurring after tirzepatide administration 1, 2
- One patient developed episodic lip angioedema and generalized urticaria 4 days after dose escalation to 10 mg, which persisted despite steroids and antihistamines, resolving only after drug discontinuation 1
- Another case involved anaphylaxis with generalized urticaria, facial angioedema, and possible biphasic reaction after the first dose 2
- Pharmacovigilance analysis of FAERS data (2022-2025) identified skin-related adverse events as emerging safety signals with tirzepatide 3
Clinical Recognition and Management
If urticaria develops on Zepbound:
- Discontinue tirzepatide immediately if urticaria is accompanied by angioedema, respiratory symptoms, or systemic signs
- Treat with standard antihistamine therapy (H1-blockers); severe reactions may require epinephrine and corticosteroids
- Document the reaction timing relative to dosing and any dose escalations
- Consider allergy evaluation with intradermal testing if alternative GLP-1 receptor agonist therapy is needed 1
Important Caveats
Timing considerations:
- Median time-to-onset for adverse events with tirzepatide is approximately 6 days, with early failure profile indicating reactions can occur within the first week 3
- Reactions may occur after tolerating lower doses, particularly following dose escalation 1
Cross-reactivity:
- Tirzepatide-specific hypersensitivity does not necessarily predict reactions to other GLP-1 receptor agonists
- Patients with confirmed tirzepatide allergy have successfully transitioned to semaglutide after negative intradermal testing and supervised challenge 1
Distinguish from other causes:
- The most common side effects of tirzepatide remain gastrointestinal (nausea, vomiting, diarrhea), not dermatologic 4, 5, 4
- Injection-site reactions occur more commonly than systemic hypersensitivity 6
While urticaria is not listed among the most common side effects in major clinical guidelines 4, emerging post-marketing surveillance and case reports confirm it as a recognized, albeit uncommon, adverse reaction requiring clinical vigilance and appropriate management.